Image

Global Seborrheic Dermatitis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Seborrheic Dermatitis Market, By Treatment (Anti-inflammatory, Antifungal, Corticosteroid Lotions, Sulfur Products, Others), Dosage Form (Creams, Shampoos, Ointments, Gels, Others), Route of Administration (Oral, Topical, Parenteral, Others), Diagnosis (Physical Examination, Biopsy, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

 

Seborrheic Dermatitis Market

Market Analysis and Size

In recent years, the seborrheic dermatitis market is anticipated to proliferate during the forecast period. In the United States and worldwide, seborrheic dermatitis is a prevalent dermatological condition. Immunocompromised patients, such as HIV patients, lymphoma patients, and organ transplant recipients, are more likely to develop seborrheic dermatitis. Dandruff is a minor variant of seborrheic dermatitis. Compared to seborrheic dermatitis, dandruff is far more widespread, affecting almost half of the global adult population. According to the National Center for Biotechnology Information, dandruff prevalence was 81–95 percent in African Americans, 66–82 percent in Caucasians, and 30–42 percent in Chinese in a research conducted in the United States and China.

Data Bridge Market Research analyses that the seborrheic dermatitis market was valued at USD 2.16 billion in 2021 and is expected to reach USD 4.98 billion by 2029, registering a CAGR of 11.00% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

The skin illness seborrheic dermatitis develops an itchy rash with flaky scales. On light skin, it causes redness, and on darker skin, it causes light patches. Dandruff, cradle cap, seborrhea, seborrheic eczema, and seborrheic psoriasis are some of the other names for it. It may resemble psoriasis, eczema, or an allergic reaction in appearance. Seborrheic dermatitis is more common in newborns and adults aged 30 to 60. It's more frequent in men than in women, and it's more common in persons who have oily skin.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Anti-inflammatory, Antifungal, Corticosteroid Lotions, Sulfur Products, Others), Dosage Form (Creams, Shampoos, Ointments, Gels, Others), Route of Administration (Oral, Topical, Parenteral, Others), Diagnosis (Physical Examination, Biopsy, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (US)GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Baxter (US), Hikma Pharmaceuticals PLC (UK), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Monarch Pharmachem (US)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Seborrheic Dermatitis Market Dynamics

Drivers

  • Increasing prevalence of dermatological diseases

The rising prevalence of dermatological diseases is estimated to enhance the seborrheic dermatitis market's growth. Eczema, psoriasis and tinea versicolor are the various skin diseases that increase the risk of seborrheic dermatitis, further propelling the market's growth rate.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of the seborrheic dermatitis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get seborrheic dermatitis, further estimated to enhance the market's growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the seborrheic dermatitis market. Additionally, rising incidences of depression and high alcohol consumption will expand the seborrheic dermatitis market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the seborrheic dermatitis market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the seborrheic dermatitis market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. Limited primary care services and lack of healthcare infrastructure in developing economies will challenge the seborrheic dermatitis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This seborrheic dermatitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the seborrheic dermatitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

SD is a widespread dermatological condition in the United States and worldwide. Its prevalence rises at three different ages: in the first three months of life, during puberty, and in maturity, having an apex between the ages of 40 and 60. SD affects the scalp, face, and diaper area in infants up to three months old. Up to 42% of people are affected. SD affects the scalp and other seborrheic areas of the face, upper chest, axillae, and inguinal folds in adolescents and adults. The prevalence is 1–3% of the general adult population. Men are affected more commonly than women in all age groups, implying that SD is linked to sex hormones such as androgens.

Seborrheic dermatitis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Seborrheic Dermatitis Market

Over the projected period, the seborrheic dermatitis market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing many people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the seborrheic dermatitis market.

Recent Development

  • In July 2021, Arcutis Biotherapeutics, Inc. had announced the enrollment of first patient in its single pivotal Phase 3 clinical trial estimating topical roflumilast foam (ARQ-154) as a main treatment for seborrheic dermatitis. The Company is developing Roflumilast foam, a once-daily topical foam formulation of roflumilast, a highly powerful and selective phosphodiesterase type 4 (PDE4) inhibitor, for seborrheic dermatitis.

Global Seborrheic Dermatitis Market Scope

The seborrheic dermatitis market is segmented on the basis of treatment, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Anti-inflammatory
  • Antifungal
  • Corticosteroid Lotions
  • Sulfur Products
  • Others

Diagnosis

  • Physical Examination
  • Biopsy
  • Others

Dosage form

  • Creams
  • Shampoos
  • Ointments
  • Gels
  • Others

Route of Administration

  • Oral
  • Topical
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Pipeline Analysis                                

COMPANY

DRUG

PHASE

ROUTE OF ADMINISTRATION

MECHANISM OF ACTION

Arcutis Biotherapeutics, Inc

ARQ-154

Phase 3

Topical

Type 4 cyclic nucleotide phosphodiesterase inhibitors

MatriSys Bio

MSB-7154

Preclinical

Topical

Microbiome modulators and Bacteria replacements

Amorepacific

PAC 14028

Phase 2

Topical

TRPV1 receptor antagonists

DermBiont

DBI-002

Phase 2

Topical

Microbiome modulators

Seborrheic Dermatitis Market Regional Analysis/Insights

The seborrheic dermatitis market is analyzed and market size insights and trends are provided by country, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the seborrheic dermatitis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the seborrheic dermatitis market because of the growing prevalence of skin disorders in this region. Additionally, rising healthcare expenditure will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to easily availability of over-the-counter (OTC) drugs and surging incidences of skin diseases by herbal and synthetic medicines in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Seborrheic Dermatitis Market Share Analysis

The Seborrheic dermatitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to seborrheic dermatitis market.

Some of the major players operating in the seborrheic dermatitis market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • Allergan (Ireland)
  • AstraZeneca (UK)
  • AbbVie Inc. (US)
  • Johnson & Johnson Private Limited (US)
  • Cipla Inc. (US)  
  • Abbott (US)
  • Merck KGaA (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (UK)
  • LEO Pharma A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Monarch Pharmachem (US)
  • Baxter (US)

Research Methodology: Global Seborrheic Dermatitis Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for Seborrheic Dermatitis Market is expected USD 4.98 billion by 2029.
The Seborrheic Dermatitis Market is to grow at a CAGR of 11.00% during the forecast by 2029.
The major players operating in the Seborrheic Dermatitis Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (US)GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Baxter (US), Hikma Pharmaceuticals PLC (UK), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Monarch Pharmachem (US).
The major countries covered in the Seborrheic Dermatitis Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.